Clinical Trial Update: A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma [Phase 4]

View source ↗

Summary

Phase 4 clinical study evaluating disitamab vedotin with penpulimab as neoadjuvant therapy for HER2-expressing cisplatin-intolerant bladder urothelial carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Bladder Urothelial Carcinoma

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Penpulimab

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Bladder Cancer | Phase 4 | Status: NOT_YET_RECRUITING